BACKGROUND: Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or concerns. Few studies have comprehensively assessed self-reported concerns between those who currently, previously or have never received AET. The study objective is to describe self-reported physical and emotional concerns of breast cancer survivors who are current, prior, or never-recipients of AET. METHODS: Secondary analysis was performed on a subset of survey data collected in the 2010 LIVESTRONG Survey. Breast cancer survivors (n = 1,013, mean 5.4 years post-diagnosis) reported on 14 physical and eight emotional concerns that began after diagnosis and were experienced within 6 months of participation in the survey. Bivariate analyses examined the prevalence of each concern by AET status. The relationships between AET and burden of physical or emotional concerns were modeled with logistic regression. RESULTS: More than 50% of the participants reported currently experiencing cognitive issues, fatigue, fear of recurrence, emotional distress, and identity/grief issues. Thyroid dysfunction and stigma concerns were more common among participants with prior AET (p < 0.01), while fear of recurrence, emotional distress, and concern about appearance were more common among those currently receiving AET (p < 0.01). Fatigue, sexual dysfunction, and pain were more common among prior and current AET recipients (p < 0.01). In adjusted models, receipt of AET was associated with a higher number of physical, but not emotional concerns. A higher number of concerns was associated with younger age, having children, receipt of chemotherapy, longer duration of cancer treatment, and shorter time since diagnosis (p < 0.01). CONCLUSIONS: Breast cancer survivors who received AET were at risk of developing a variety of physical and emotional concerns, many of which persisted after treatment. These findings suggest the importance of developing individualized, supportive resources for breast cancer survivors.
BACKGROUND:Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or concerns. Few studies have comprehensively assessed self-reported concerns between those who currently, previously or have never received AET. The study objective is to describe self-reported physical and emotional concerns of breast cancer survivors who are current, prior, or never-recipients of AET. METHODS: Secondary analysis was performed on a subset of survey data collected in the 2010 LIVESTRONG Survey. Breast cancer survivors (n = 1,013, mean 5.4 years post-diagnosis) reported on 14 physical and eight emotional concerns that began after diagnosis and were experienced within 6 months of participation in the survey. Bivariate analyses examined the prevalence of each concern by AET status. The relationships between AET and burden of physical or emotional concerns were modeled with logistic regression. RESULTS: More than 50% of the participants reported currently experiencing cognitive issues, fatigue, fear of recurrence, emotional distress, and identity/grief issues. Thyroid dysfunction and stigma concerns were more common among participants with prior AET (p < 0.01), while fear of recurrence, emotional distress, and concern about appearance were more common among those currently receiving AET (p < 0.01). Fatigue, sexual dysfunction, and pain were more common among prior and current AET recipients (p < 0.01). In adjusted models, receipt of AET was associated with a higher number of physical, but not emotional concerns. A higher number of concerns was associated with younger age, having children, receipt of chemotherapy, longer duration of cancer treatment, and shorter time since diagnosis (p < 0.01). CONCLUSIONS:Breast cancer survivors who received AET were at risk of developing a variety of physical and emotional concerns, many of which persisted after treatment. These findings suggest the importance of developing individualized, supportive resources for breast cancer survivors.
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Nancy E Avis; Kevin W Smith; Sarah McGraw; Roselyn G Smith; Vida M Petronis; Charles S Carver Journal: Qual Life Res Date: 2005-05 Impact factor: 4.147
Authors: C Giani; P Fierabracci; R Bonacci; A Gigliotti; D Campani; F De Negri; D Cecchetti; E Martino; A Pinchera Journal: J Clin Endocrinol Metab Date: 1996-03 Impact factor: 5.958
Authors: Helen G Mar Fan; Nadine Houédé-Tchen; Qi-Long Yi; Irene Chemerynsky; Fiona P Downie; Kathryn Sabate; Ian F Tannock Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Laura C Pinheiro; Stephanie B Wheeler; Katherine E Reeder-Hayes; Cleo A Samuel; Andrew F Olshan; Bryce B Reeve Journal: J Oncol Pract Date: 2017-03-14 Impact factor: 3.840
Authors: Cleo A Samuel; Kea Turner; Heidi A S Donovan; Ellen Beckjord; Alexandra Cardy; Mary Amanda Dew; G J van Londen Journal: Support Care Cancer Date: 2017-07-06 Impact factor: 3.603
Authors: Laurence Leysen; David Beckwée; Jo Nijs; Roselien Pas; Thomas Bilterys; Sofie Vermeir; Nele Adriaenssens Journal: Support Care Cancer Date: 2017-08-10 Impact factor: 3.603
Authors: Neha Verma; Amanda L Blackford; Elissa Thorner; Jennifer Lehman; Claire Snyder; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2022-10-05 Impact factor: 4.624
Authors: Leslie R Schover; Marleen van der Kaaij; Eleonora van Dorst; Carien Creutzberg; Eric Huyghe; Cecilie E Kiserud Journal: EJC Suppl Date: 2014-05-29